<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>3-Hydroxy-3-methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> (HMG CoA) reductase inhibitors, commonly known as <z:chebi fb="0" ids="35664">statins</z:chebi>, are widely used clinically for their <z:chebi fb="23" ids="18059">lipid</z:chebi> lowering properties </plain></SENT>
<SENT sid="1" pm="."><plain>Recent evidence shows that <z:chebi fb="0" ids="35664">statins</z:chebi> are also effective in ameliorating <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e>, which occurs as sequelae of <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This review focuses on the pleiotropic effects of <z:chebi fb="0" ids="35664">statins</z:chebi>, and the putative mechanisms involved in <z:chebi fb="0" ids="35664">statin</z:chebi> mediated attenuation of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>